Health-care companies rose amid earnings optimism. Eli Lilly added to gains, amid a sense that the maker of Mounjaro and Zepbound is pulling away from its competition in the obesity-drug boom. Shares ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

GLP-1 drugs, synthetic versions of a natural hormone, are revolutionizing weight loss and type 2 diabetes treatment. By ...

Merck and Eisai announced termination of a phase III trial of pembrolizumab plus lenvatinib (Lenvima) and transarterial chemoembolization (TACE) for unresectable liver cancer after an interim analysis ...

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

Lilly predicts it will achieve an adjusted profit of between $23.00 and $23.70 per share this year, an increase on its ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly.

Some guys are getting this promising new weight loss drug on the grey market. Here's what it does and the risks of taking it ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Pfizer said on Friday it had filed a lawsuit against Metsera and Novo Nordisk , saying Metsera breached its merger agreement ...